Litigation

Celgene Corporation v. Natco Pharma Ltd. et al.

settled/consent judgment

2:12-cv-04571

Court
D.N.J.
Filed
2012-07-20
Terminated
2016-01-04

Patents at issue (2)

Summary

Celgene asserted U.S. 7,977,357 against Natco, Arrow, and Watson in a REVLIMID ANDA litigation. The case settled and a consent judgment entered Jan. 4, 2016 dismissed claims with prejudice and enjoined Natco from generic lenalidomide except under license. The May 27, 2014 Markman opinion in the Natco litigation also construed 'Form A' for the '357 and '598 patents.

Case overview & background

Plain-language overview of the case: parties, accused product, patents at issue, and why the suit matters.

Save related patent research

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Key legal developments & outcome

Major rulings, motions, claim construction, settlements, and the present posture or final disposition.

Save related patent research

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

In the news

What the press has reported about this case, summarized with links to the source articles.

Save related patent research

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Plaintiff representatives

Counsel of record for the plaintiff(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).

Save related patent research

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Defendant representatives

Counsel of record for the defendant(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).

Save related patent research

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).